Loading
A phase 1/2 trial of Cetrelimab and Amivantamab in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05908734 by Janssen Research & Development, LLC, with 71 participants enrolled, started 2023-05-18 and due to reach its primary completion in 2027-01-31. Interventions recorded: Cetrelimab and Amivantamab.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.